Spotlight On... Huya pads its pipeline with immuno-oncology deal; AstraZeneca's former R&D hub finds new life; and more...

Chinese-American biotech Huya Biosciences in-licensed a handful of early-stage treatments with potential in immuno-oncology, padding its pipeline behind a lead cancer therapy. The company is paying an undisclosed sum to China's Fudan University for the rest-of-world rights to some therapies that target the IDO pathway to help the immune system better attack malignancies. Huya said the deal is designed to augment its work on HBI-8000, an oral treatment that targets enzymes called HDACs, which play a role in regulating the growth of tumor cells. The drug is approved in China, and Huya has partnered with Eisai to develop it throughout Asia in a deal worth up to $270 million. More

@FierceBiotech: Tiny Celator surges on promising cancer data and preps an FDA submission. Article | Follow @FierceBiotech

@JohnCFierce: Gee, Lilly drops function as a co-primary endpoint for sola. Anyone a wee bit nervous? Release | Follow @JohnCFierce

> Three years after AstraZeneca ($AZN) closed its R&D hub in Cheshire, U.K., the site has found new life as the home of a public-private partnership between academia and small biotech companies. News

> The boom in microbiomics has spread to the field of immuno-oncology, as recent studies show gut bacteria could play a role in how the body responds to tumors. Story

Medical Device News

@FierceMedDev: Anne Wojcicki, Elizabeth Holmes, Andrew Conrad make 2016's most influential people in biopharma list. FierceBiotech feature | Follow @FierceMedDev

@VarunSaxena2: FDA panel set to review its first bioresorbable stent, Abbott's Absorb. Report | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Hospitals join drug price-fighting battalion with plans to crack down on spending. Report | Follow @EmilyWFierce

> NIH-funded researcher making progress on nature-inspired 'smart' contact lens. Story

> GE Healthcare JV rolls out digital pathology software for cancer diagnosis. More

> Philips readies for mid- to high-single-digit HealthTech growth with reorg, lighting disposal. Article

Pharma News

@FiercePharma: ICYMI yesterday: Patent challenger Bass wins another review bid, this time on Acorda's Ampyra. Story | Follow @FiercePharma

@CarlyHFierce: Ex-Sanofi, Schering CEOs were on a short list to replace Valeant chief Pearson: WSJ. More | Follow @CarlyHFierce

> Zydelig 'dead in the water' after trial deaths force Gilead to stop frontline studies. Report

> Specialty-drug spending set for double-digit leaps over the next 3 years: Express Scripts. More

Drug Delivery News

> 'Smart' diabetes patch uses real beta cells to react to blood sugar and release insulin. Story

> Artificial liposomes bypass immune system to release cardio drugs. More

> Harvard team develops blood-brain-barrier-on-a-chip to study drug delivery. Report

> EyeGate adds drug-delivering hydrogel to its pipeline with acquisition of Jade Therapeutics. Story

> Eli Lilly reports promising early-stage results for its fast-acting insulin formulation. Article

Pharma Manufacturing News

> Lupin plant in Goa smacked by the FDA. Report

> China's FDA urged to get track and trace system in place. Item

> Iran drugmaker agrees to build plant in Azerbaijan. Report

> Pfizer, Abbott cough syrups banned by Indian regulator in fight over opiates. Article

> Amgen strikes deal with Patheon for 'flexible manufacturing capacity.' Story

Pharma Asia News

> India still reviewing prospects for mandated cuts in drug prices. Item

> GSK's Witty hears the rhythm in China's drumbeat for lower prices. More

> India lifts alert on Roche's Avastin use for eye injection. Story

> SK Bio's epilepsy drug gets U.S. FDA exemption from PhIII efficacy step. News

> India's Dr. Reddy's works with Turkey's TR-Pharm on biosimilars. Article